Beijing chaoyang hospital-affiliate of captial medical university
Beijing, Beijing Municipality, 100020, China
NCT Number: NCT01121367
This study is to evaluate the expression of biological markers in induced sputum and peripheral blood T lymphocytes of patients with combined pulmonary fibrosis and emphysema (CPFE). The features of CPFE would be observed, including pulmonary function tests and fractional exhaled nitric oxide (FENO).
Looking for future studies?
Notify Me50 year–90 year
All sexes
Observational
Beijing, Beijing Municipality, 100020, China
A new disease including concomitant upper-lobe emphysema and lower-lobe fibrosis in radiology has been defined as (combined pulmonary fibrosis and emphysema, CPFE). CPFE has distinct clinical characteristics with the emphysema and the pulmonary fibrosis, including gender, age, clinical manifestation, pulmonary function tests and prognosis.
Normally Th1/Th2 is balanced. However, patients with emphysema had a significantly higher expression of Th1. On the other hand, higher expression of Th2 is involved in the development of pulmonary fibrosis. The expressions of Th1 and Th2 were proved to play a central role in pathogenesis of emphysema and pulmonary fibrosis, while are still unknown in patients of combined pulmonary fibrosis and emphysema. The study would observe the Th1/Th2 expression, pulmonary function tests , fractional exhaled nitric oxide (FENO)and other features in CPFE patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: six months
Time frame: six months
Time frame: six months
Beijing Chao Yang Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02439528
Combined Pulmonary Fibrosis and Emphysema Syndrome, Disease
Bron, France
View Trial DetailsNCT01615484
Alpha-1 Antitrypsin Deficiency, Bronchial Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04930289
COPD, Chronic Disease
Phoenix, Arizona, United States
View Trial DetailsNCT06528418
Abscess, Actinomycetales Infections
Guangzhou, Guangdong, China
View Trial Details